Biotech startup lines up more cash to steer its NASH drug through stormy seas

Paul Schloesser

Associate Editor

In January 2020, Dutch NASH-focused biotech NorthSea Therapeutics raised $40 million in a Series B to progress its lead candidate icosabutate, a structurally-engineered fatty compound …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biotech startup lines up more cash to steer its NASH drug through stormy seas

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

Apollo makes a deal worth up to $926M; Abeona resubmits gene therapy

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Biotech start­up lines up more cash to steer its NASH drug through stormy seas

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Biotech startup lines up more cash to steer its NASH drug through stormy seas

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

Apollo makes a deal worth up to $926M; Abeona resubmits gene therapy

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?